Early Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been diagnosed with multiple myeloma (a type of blood cancer) confirmed by standard medical criteria, and whose cancer cells show a specific protein called BCMA, detected by laboratory testing
• People who have already received at least 2 different rounds of treatment for multiple myeloma, with at least one full treatment cycle completed for each round, and whose disease has gotten worse within 12 months of their most recent treatment — or whose disease has stopped responding to two common types of myeloma treatment and has worsened within 2 months of their last treatment
• People whose disease can be measured through blood, urine, or imaging tests at the time of screening, meeting specific levels set by the trial (confirm with trial site for exact measurements)
• People with a general health status rated as reasonably functional (on a standard medical scale called ECOG, scored 0–2), and who are expected to live at least 3 months
• People whose bone marrow blood cell counts meet minimum levels at screening, including red blood cells, white blood cells, platelets, and certain immune cells (confirm with trial site for exact values)
• People whose kidneys are working well enough, with kidney filtration function at or above a certain level (confirm with trial site for exact value)
• People whose liver function test results fall within acceptable ranges at screening
• People whose heart function meets minimum requirements, including normal heart pumping ability and no significant heart rhythm or fluid problems detected
• People whose lung function meets minimum requirements, including adequate oxygen levels in the blood and no significant fluid around the lungs
• Women who could become pregnant must have a negative pregnancy test before joining and must not be breastfeeding
• People of childbearing potential (male or female) must agree to use effective contraception from the time of signing consent until one year after receiving the study treatment
• People of childbearing potential (male or female) must agree not to donate sperm, eggs, or other reproductive material from the time of signing consent until one year after receiving the study treatment
• People (or their legal representative) who are willing and able to provide written consent to take part in the study

Who may not be able to join:

• People who have recently received certain other cancer treatments, including targeted therapies, experimental drugs, immune therapies, chemotherapy, or radiation, within specific time periods before joining (confirm with trial site for exact timeframes)
• People who received a donor stem cell transplant within 6 months, or their own stem cell transplant within 3 months, before the planned treatment
• People who have had another type of cancer, unless it was fully treated with no signs of disease for at least 2 years before joining, or was a type of non-melanoma skin cancer that was adequately treated with no signs remaining
• People who have previously been treated with a specific type of virus-based therapy using VSVG pseudotype virus
• People with serious active infections (such as bacterial, viral, or fungal) that are not under control at the time of screening
• People who have active hepatitis B, hepatitis C, HIV, or syphilis infections, as determined by specific blood tests
• People with serious heart conditions, including severe heart failure, a recent heart attack or heart surgery within 6 months, significant irregular heartbeats, or a history of significant heart muscle disease
• People with certain other serious health conditions, including a primary immune system disorder, a stroke or seizure within the past 6 months, clear signs of dementia or significant mental confusion, or a history of Parkinson's disease
• People who have had surgery within 2 weeks before treatment, or who have surgery planned within 2 weeks after treatment (except minor procedures done under local anaesthetic)
• People who have received a live vaccine within 1 month before treatment
• People with a known serious allergic reaction to the study drug (ESO-T01) or its ingredients
• People with a known serious allergic reaction to a medication called Tocilizumab
• People for whom a suitable vein cannot be found for delivering the treatment
• People who have any other condition that the trial doctor considers would make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.